The Scribe Team (L to R: Benjamin Oakes, Brett Staahl, Svetlana Lucas, Jennifer Doudna, David Savage)

Scribe, Jen­nifer Doud­na's newest start­up, nabs a mega-round and a vo­cal in­vestor

Near­ly a decade ago, when the first CRISPR com­pa­nies start­ed look­ing for cap­i­tal, Be­hzad Ag­haz­adeh passed.

Ag­haz­adeh, one of biotech’s more opin­ion­at­ed in­vestors, had in­vest­ed in gene edit­ing be­fore, but he had reser­va­tions about these com­pa­nies: How would they nav­i­gate the patent jun­gle that cropped up around CRISPR-Cas9? How read­i­ly could they ac­tu­al­ly turn this bac­te­r­i­al-de­rived sys­tem in­to a hu­man ther­a­py? He main­tains those con­cerns, even with those com­pa­nies now worth over $1 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.